Evidence map›Paper›PMID 33539919›Full record

ArticleThe Journal of biological chemistry

Optimized binding of substituted quinoline ALLINIs within the HIV-1 integrase oligomer.

Jian Sun, Krunal Patel, Jared Hume, Julie A Pigza, Matthew G Donahue, Jacques J Kessl

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Mapping the vRNA Interaction with HIV-1 Integrase.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Review
  5. Scalable Preparation of the Masked Acyl Cyanide TBS-MAC.Molecules (Basel, Switzerland) · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jian SunDepartment of Chemistry and Biochemistry, University of Southern Mississippi, Hattiesburg, Mississippi, USA; Center for Molecular and Cellular Biosciences, University of Southern Mississippi, Hattiesburg, Mississippi, USA.
Krunal PatelDepartment of Chemistry and Biochemistry, University of Southern Mississippi, Hattiesburg, Mississippi, USA; Center for Molecular and Cellular Biosciences, University of Southern Mississippi, Hattiesburg, Mississippi, USA.
Jared HumeDepartment of Chemistry and Biochemistry, University of Southern Mississippi, Hattiesburg, Mississippi, USA.
Julie A PigzaDepartment of Chemistry and Biochemistry, University of Southern Mississippi, Hattiesburg, Mississippi, USA.
Matthew G DonahueDepartment of Chemistry and Biochemistry, University of Southern Mississippi, Hattiesburg, Mississippi, USA.
Jacques J KesslDepartment of Chemistry and Biochemistry, University of Southern Mississippi, Hattiesburg, Mississippi, USA; Center for Molecular and Cellular Biosciences, University of Southern Mississippi, Hattiesburg, Mississippi, USA. Electronic address: Jacques.kessl@usm.edu.
University of Southern Mississippi · US

Funding

Training and Mentoring Core P20GM103476 · NIGMS · UNIVERSITY OF SOUTHERN MISSISSIPPI · PI MICHAEL R GARRETT · 2012 to 2026
$60.2M
New Inhibitors Targeting HIV-1 Integrase During Viral MaturationR01AI140985 · NIAID · UNIVERSITY OF SOUTHERN MISSISSIPPI · PI Jacques J. Kessl · 2019 to 2026
$2.2M
Asymmetric Synthesis of Bioactive Nitrogen HeterocyclesR15GM129751 · NIGMS · UNIVERSITY OF SOUTHERN MISSISSIPPI · PI DONAHUE, MATTHEW GARRETT · 2018 to 2018
$439k
NIAID NIH HHS R01 AI140985NIGMS NIH HHS P20 GM103476NIGMS NIH HHS R15 GM129751
6 · The paper itself

Abstract

During the integration step, human immunodeficiency virus type 1 integrase (IN) interacts with viral DNA and the cellular cofactor LEDGF/p75 to effectively integrate the reverse transcript into the host chromatin. Allosteric human immunodeficiency virus type 1 integrase inhibitors (ALLINIs) are a new class of antiviral agents that bind at the dimer interface of the IN catalytic core domain and occupy the binding site of LEDGF/p75. While originally designed to block IN-LEDGF/p75 interactions during viral integration, several of these compounds have been shown to also severely impact viral maturation through an IN multimerization mechanism. In this study, we tested the hypothesis that these dual properties of ALLINIs could be decoupled toward late stage viral replication effects by generating additional contact points between the bound ALLINI and a third subunit of IN. By sequential derivatization at position 7 of a quinoline-based ALLINI scaffold, we show that IN multimerization properties are enhanced by optimizing hydrophobic interactions between the compound and the C-terminal domain of the third IN subunit. These features not only improve the overall antiviral potencies of these compounds but also significantly shift the ALLINIs selectivity toward the viral maturation stage. Thus, we demonstrate that to fully maximize the potency of ALLINIs, the interactions between the inhibitor and all three IN subunits need to be simultaneously optimized.

Indexed as

Allosteric RegulationAntiviral AgentsHEK293 CellsHIV-1HIV IntegraseHIV Integrase InhibitorsHumansIntercellular Signaling Peptides and ProteinsModels, MolecularProtein BindingProtein MultimerizationQuinolinesVirus IntegrationVirus ReplicationAntiviral AgentsHIV IntegraseHIV Integrase InhibitorsIntercellular Signaling Peptides and Proteinslens epithelium-derived growth factorp31 integrase protein, Human immunodeficiency virus 1quinolineQuinolinesALLINIantiviral agentdrug designhuman immunodeficiency virusintegraseoligomerizationprotein–protein interactionquinoline

Identifiers

PMID33539919
PMCPMC7949159
OpenAlexW3128122376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.